Johnson & Johnson's androgen receptor inhibitor Erleada (apalutamide) was approved by the US Food and Drug Administration for a new indication in patients with metastatic castration-sensitive prostate cancer (mCSPC), the company announced on 17 September, giving it a small lead in the indication over Xtandi (enzalutamide).
Erleada is J&J's newer androgen receptor inhibitor, which the company hopes can fill some of the gap left by the...